Heart failure and cardiac imaging: Choosing wisely in the era of multimodality imaging

Frank Flachskampf, Tomasz Baron

Departments of Medical Sciences, Uppsala University, and Department of Cardiology and Clinical Physiology, Uppsala University Hospital; Uppsala, Sweden
1Centre for Medical Imaging, Uppsala University Hospital; Uppsala, Sweden

Introduction

Heart failure is the common final outcome of many heart diseases. Cardiac imaging plays a central role in its diagnosis and etiological work-up. Given the large array of imaging modalities, as well as structural and functional parameters, devising a diagnostic strategy that provides diagnostic accuracy without wasting resources can be challenging. “Multimodality imaging” has become a popular buzzword without a clear meaning, except for different modalities showing different aspects, which sometimes may be helpful and sometimes not. Is multimodality imaging per se diagnostically superior? When should we escalate from echocardiography to other modalities? In this viewpoint article, we attempt to provide guidelines on the rational deployment of modern imaging armamentarium in heart failure.

The role of echocardiography in the diagnosis of heart failure

In patients with symptoms suggestive of heart failure, after the history taking, physical examination, electrocardiogram evaluation, and perhaps drawing blood for natriuretic peptides, the next diagnostic step is unquestionably an echocardiogram (1, 2). This can usually – unless in special circumstances, such as forbidding acoustical windows – address the following fundamental questions:

- What are the left ventricular size, ejection fraction, and global longitudinal strain?
- Are there signs of diastolic left ventricular dysfunction?
- Are there regional wall motion abnormalities suggesting coronary artery disease (CAD)?
- Is there left ventricular remodeling or hypertrophy?
- Are there structural abnormalities suggesting cardiomyopathy?
- Are there right ventricular abnormalities, congenital heart disease (e.g., atrial septal defect), or other major structural abnormalities?

The echocardiographic answers to these questions usually allow, together with other clinical information, to arrive at least at a tentative diagnosis and to start therapy. In some cases, standard echocardiography should be enhanced by left heart contrast (e.g., to better see the apex of the left ventricle) or by transesophageal echocardiography (e.g., to rule out an atrial septal defect, especially a sinus venosus defect). Diastolic function assessment and strain imaging provide additional important clues for the diagnosis of heart failure. For example, hypertrophic cardiomyopathy is often characterized by extremely low E and e’ values because of massively disturbed relaxation, especially in the hypertrophied septum. Conversely, advanced diastolic dysfunction (restrictive transmitral profile) is typically observed in amyloidosis, which is also characterized (although not uniquely so) by the apical sparing pattern of the longitudinal strain. In addition, Anderson-Fabry disease as well as cardiac sarcoid may be associated with localized deterioration of strain, which may not be noticeable to the naked eye. Importantly, strain imaging can detect myocardial disease in the ventricles with preserved ejection fraction, and reduced global longitudinal strain (GLS) predicts the prognosis of these patients (3). The high sensitivity of reduced GLS for the incipient heart failure has further led to its integration in screening protocols for the cardiotoxicity of cancer chemotherapy and may in the future aid in better defining the beginning of heart failure in patients with severe valvular disease. However, diastolic LV function disturbances and strain

Address for correspondence: Frank Flachskampf, MD, Departments of Medical Sciences, Uppsala University, and Department of Cardiology and Clinical Physiology, Uppsala University Hospital; Akademiska Inst.Med.Vet. ingang 40 751 85, Uppsala, Sweden
E-mail: frank.flachskampf@medsci.uu.se
Accepted Date: 31.01.2020 Available Online Date: 12.03.2020
©Copyright 2020 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2020.66745
reductions are functional, quite unspecific “red flags,” indicating a myocardial disease, but not which one.

Thus, echocardiography (perhaps combined with coronary angiography) seemed to provide all necessary information in heart failure, except for myocarditis, sarcoidosis, and others, which essentially required myocardial biopsy for a more accurate diagnosis. However, cardiac imaging has undergone rapid and diverse development over the last decades, and increasingly, we must recognize that this traditional approach is incomplete and will lead to missed diagnoses if current diagnostic possibilities are not explored (Table 1). Simultaneously, it is important to “choose wisely,” as the American College of Cardiology (4) has launched a campaign to contain the overuse of imaging, and thereby, strengths and weaknesses of the imaging modalities at our disposition should be understood.

The new players in the imaging arena
Cardiovascular magnetic resonance (CMR) is the most versatile “advanced imaging” modality. Beyond its more precise and reliable measurement of volumes and ejection fraction of both chambers, than echocardiography, the great strength of CMR is its ability to characterize the tissue. This is not the same as histology, but still allows a far better understanding of myocardial tissue changes than all other modalities. After gadolinium contrast application, localized increased extracellular space (ECV) can be identified as “late gadolinium enhancement” (LGE). These localized increases occur from replacement fibrosis after a myocardial infarction. Subendocardially located late gadolinium enhancement in the perfusion territory of a coronary accurately identifies and quantitates infarct scars. However, LGE can also be found in typical patterns with myocarditis (Fig. 1), cardiomyopathies, and cardiac storage diseases like amyloidosis, and is associated with the prognosis and therefore a very useful diagnostic feature. A further major advancement in tissue characterization by CMR has occurred through quantitative pixel-by-pixel determination (so-called parametric mapping) of the relaxation time constants (in milliseconds) T1, T2, T2*, and the estimate of ECV (in percent), which can be measured using the pre-contrast and post-contrast T1. These parameters reflect both extra- and intracellular tissue features, related to the chemical composition of the tissue, and thus provide clues as regards the amount of water in the myocardial tissue (e.g., inflammation and edema), the presence of large molecules (e.g., sphingolipids in Anderson-Fabry disease), iron, and other factors (5-8). They provide time constants in absolute values, not just gray levels in the image, and therefore also can identify diffuse changes, such as in generalized fibrosis, which LGE cannot visualized. Relaxation times and ECV cannot unambiguously identify specific diseases or histologies. However, for some diseases, the “signature” can be quite characteristic, such as amyloid (Fig. 2) with long T1 and Anderson-Fabry disease with very short T1 times (at least in early disease) or hemochromatosis with shortened T2* times. Although the methodology is machine and protocol dependent and subject

| Table 1. Newly detected heart failure: factors and mechanisms to be ruled out/in. Modified from Krister Lindmark, Umeå, Sweden |
|---------------------------------------------------------------|
| **Recommended imaging test(s)** | **Other helpful tests in addition to history taking, physical exam, and ECG** |
| Hypertensive heart disease | Echo |  |
| CAD | (Echo), CT, ischemia testing |  |
| Valvular heart disease | Echo, (CMR) |  |
| Tachycardia (ventricular or supraventricular) | Echo |  |
| Hypertrophic cardiomyopathy | Echo, CMR | Genotyping |
| Hypothyroidism | Echo | Laboratory |
| Myocarditis | CMR | Laboratory (troponin, virus serology), biopsy |
| Hemochromatosis | CMR | Laboratory |
| Hereditary dilated cardiomyopathy | Echo, CMR | Genotyping |
| Cardiac amyloidosis | (Echo), SPECT, PET, CMR | Biopsy, laboratory (for light-chain amyloidosis) |
| Andersen-Fabry | (Echo), CMR | Laboratory |
| Sarcoidosis | CMR, PET | Laboratory (angiotensin-converting enzyme), biopsy |
| Postpartum cardiomyopathy | Echo |  |
| Chemotherapy | Echo, CMR | Laboratory |
| Drug toxicity | Echo | Laboratory |
| High alcohol intake | Echo | Laboratory (phosphatidylethanol) |

CMR - cardiovascular magnetic resonance; CT - computed tomography; PET - positron emission tomography
to many possible errors, the parametric imaging constitutes a major advancement in cardiac imaging and the closest we can come with “virtual histology” today. Limitations and contraindications of CMR apply, such as image deterioration with arrhythmia, renal impairment for gadolinium contrast application, non-compatible cardiac implants like some pacemakers, and claustrophobia.

Other very important new players are cardiac computed tomography (CT). Its main task is the exclusion of coronary artery disease by noninvasive coronary angiography, and the stratification of cardiovascular risk by quantifying coronary calcification, typically using the Agatston score. Although the latter is only indirectly related to heart failure, information on cardiovascular risk and CAD extent is indispensable for the management of patients with heart failure. CT is also limited in the presence of atrial fibrillation or renal impairment and involves radiation exposure.

Remarkably, both CMR and CT also permit determination of myocardial strain, although this is still a research tool to date.

The third modality increasingly involved in the diagnostic work-up of patients with heart failure is nuclear imaging. Apart from its classic function of identifying permanent or stress-inducible myocardial perfusion defects as signs of CAD, it has several unique applications in the field of heart failure, most importantly:

1) $^{99}$Tc-diphosphonate SPECT, used traditionally in identifying sites of high bone metabolism (“bone scan” for bone metastases), visualizes cardiac transthyretin amyloidosis.

2) Positron emission tomography (PET) can determine absolute regional myocardial perfusion and perfusion reserve and provide functional information about both epicardial coronary and small-vessel function.

3) PET can also be used to assess myocardial viability by detecting low regional perfusion areas but preserved metabolism (“mismatch”), separately measuring perfusion and metabolism using different tracers.

4) PET can detect all types of cardiac amyloidosis (9) using specific ligands, e.g., $^{11}$C-PIB (Fig. 3) and help diagnose cardiac sarcoidosis by visualizing cardiac areas of high metabolism corresponding to sarcoid granulomas (10).

5) PET assessment of how well the myocyte transforms chemical into mechanical energy (myocardial external efficiency; 11), up to now still a research area.

Figure 1. Cardiovascular magnetic resonance midwall enhancement in dilated cardiomyopathy. A 57-year-old man with dilated cardiomyopathy and thin septal midwall enhancement (arrows). Top left, four-chamber view, top right, short axis view. Ejection fraction, 23%; LV end-diastolic volume, 188 mL/m$^2$; generalized hypokinesia. Bottom: magnification Fig. 1a for better visualization of midwall enhancement in basal septum.

Figure 2. Cardiovascular magnetic resonance images of a 69-year-old man with cardiac amyloidosis. a) generalized subendocardial LGE, including the atrial walls. Thickened atrial septum and pericardial effusion. LV end-diastolic volume, 67 mL/m$^2$; LV EF, 46%; and LV mass, 68 g/m$^2$ (normal). Septal native T1 1140 ms (increased), ECV 57% (massively increased). Late gadolinium enhancement image (four-chamber view) with diffuse LV subendocardial enhancement (arrows); note also interatrial septum thickening (short arrow) and pericardial effusion. b and c) Diastolic cine (steady-state free precession) frames (b, four-chamber view, c, short-axis view), showing increased wall thickness as the only pathology.
2) Heart failure with reduced ejection fraction (HFrEF). Even after ruling out CAD, a spectrum of etiologies still exists, some of them treatable, which cannot be differentiated by echocardiography. This ranges from myocarditis to familial dilated cardiomyopathies, sarcoidosis, hemochromatosis, and others. In this context, CMR allows to:

- Identify typical patterns of localized replacement fibrosis by late gadolinium enhancement such as “midwall enhancement,” with established diagnostic and prognostic implications
- Identify myocardial edema, such as in myocarditis, by conventional techniques including fat-suppression sequences (e.g., T2wSTIR) or by T1 and T2 mapping;
- Identify pathologic myocardial storage of substances, e.g., iron in hemosiderosis, which may mimic dilated cardiomyopathy.

3) Heart failure with preserved ejection fraction (HFrEF). This condition is typically caused by hypertension and involves LV concentric remodeling or concentric hypertrophy, although other remodeling patterns exist in hypertension (12). However, other diseases may also cause thickened LV walls, most prominently hypertrophic cardiomyopathy and cardiac amyloidosis. Amyloidosis may not be associated with pronounced wall thickening in its early stages. In a study where all HFrEF patients with a septal thickness >14 mm were systematically subjected to a 99Tc diphosphonate scan, 13% of them were diagnosed with cardiac amyloidosis, which had not been suspected clinically before (13). Cardiac amyloidosis can also be detected with high accuracy by PET (all forms of amyloidosis) and SPECT (mainly transthyretin amyloidosis) and can also be diagnosed (although less specifically) by CMR through LGE and increased T1 as well as ECV values. Lastly, CMR or CT provides more reproducible and robust data on LV and RV volumes and ejection fraction than echocardiography and can thus help in early cancer therapy-induced cardiotoxicity of the anthracycline type or in phenotypic borderline cases of arrhythmogenic cardiomyopathy.

Thus, contemporary imaging modalities offer striking diagnostic capabilities, which approach a “virtual myocardial histology.” They can detect amyloidosis, Anderson-Fabry, sarcoidosis, and hemochromatosis, diseases proven with treatment options. Even in diseases without clear treatment options, such as myocarditis or cardiomyopathies, decisions regarding follow-up or screening of relatives may be better informed by specialized imaging. Having a diagnosis is also a value in itself, for the patient and her/his family, and additionally may spare the patient and the healthcare system insignificant further diagnostic efforts. However, do we need to perform CMR, SPECT, or PET in each patient with heart failure and increased LV wall thickness? Probably not, if there is a good causal explanation (e.g., hypertension) and the course and clinical picture do not suggest another etiology, or if the benefit from treatment is unlikely, such as in the very old and multimorbid.

Recognizing that terms like “dilated cardiomyopathy” or “concentric hypertrophy” are relatively crude and may mask more specific, potentially treatable underlying diseases will change the practice of care for patients with heart failure (14). Therefore, we should be familiar with the possibilities afforded by the new modalities, even if they are costly and not always available. They are not infallible and do not invalidate echocardiography, which remains the most important imaging tool; however, they can be used as additional methods to help our patients.

Figure 3. A 75-year-old female patient with light-chain (AL) amyloidosis. CT-PET with 11C-PiB (courtesy Jens Sörensen, PET center, Uppsala University) showing a diffuse uptake of the radioisotope in the left ventricle.
Conflict of interest: None declared.

Peer-review: Internally peer-reviewed.

Authorship contributions: Concept – FF, T.B.; Design – N/A; Supervision – FF, T.B.; Funding – N/A; Materials – N/A; Data collection &/or processing – N/A; Analysis &/or interpretation – N/A; Literature search – FF, T.B.; Writing – FF, T.B.; Critical review – FF, T.B.

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.

2. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019; 40: 3297-317.

3. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, et al. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation 2015; 132: 402-14.

4. https://www.choosingwisely.org/wp-content/uploads/2015/02/ACC-Choosing-Wisely-List.pdf, accessed 5 January 2020.

5. Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: part I. J Cardiovasc Magn Reson 2010; 12: 71.

6. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017; 19: 75.

7. Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. Circ Res 2016; 119: 277-99.

8. Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations. JACC Cardiovasc Imaging 2019; 12 (11 Pt 2): 2332-44.

9. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013; 54: 213-20.

10. Sharma A, Okada DR, Yacoub H, Chrispin J, Bokhari S. Diagnosis of cardiac sarcoidosis: an era of paradigm shift. Ann Nucl Med 2020; 34: 87-93.

11. Sörensen J, Harms HJ, Aalen JM, Baron T, Smiseth OA, Flachskampf FA. Myocardial Efficiency: A Fundamental Physiological Concept on the Verge of Clinical Impact. JACC Cardiovasc Imaging 2019; pii: S1936-878X(19)30956-8.

12. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr 2008; 9: 809-15.

13. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-94.

14. Čelutkiene J, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R, et al. Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20: 1615-33.